AU2013306390B2 - Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis - Google Patents

Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis Download PDF

Info

Publication number
AU2013306390B2
AU2013306390B2 AU2013306390A AU2013306390A AU2013306390B2 AU 2013306390 B2 AU2013306390 B2 AU 2013306390B2 AU 2013306390 A AU2013306390 A AU 2013306390A AU 2013306390 A AU2013306390 A AU 2013306390A AU 2013306390 B2 AU2013306390 B2 AU 2013306390B2
Authority
AU
Australia
Prior art keywords
ser
gly
thr
tyr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013306390A
Other languages
English (en)
Other versions
AU2013306390A1 (en
Inventor
Liguang Chen
Bing CUI
Thomas James Kipps
Charles Prussak
George WIDHOPF
Jian Yu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of AU2013306390A1 publication Critical patent/AU2013306390A1/en
Application granted granted Critical
Publication of AU2013306390B2 publication Critical patent/AU2013306390B2/en
Priority to AU2018241099A priority Critical patent/AU2018241099B2/en
Priority to AU2020267172A priority patent/AU2020267172A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2013306390A 2012-08-24 2013-03-15 Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis Active AU2013306390B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2018241099A AU2018241099B2 (en) 2012-08-24 2018-10-04 Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
AU2020267172A AU2020267172A1 (en) 2012-08-24 2020-11-10 Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261693230P 2012-08-24 2012-08-24
US61/693,230 2012-08-24
US201261709055P 2012-10-02 2012-10-02
US61/709,055 2012-10-02
US201261709803P 2012-10-04 2012-10-04
US61/709,803 2012-10-04
PCT/US2013/032572 WO2014031174A1 (en) 2012-08-24 2013-03-15 Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2018241099A Division AU2018241099B2 (en) 2012-08-24 2018-10-04 Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis

Publications (2)

Publication Number Publication Date
AU2013306390A1 AU2013306390A1 (en) 2015-02-26
AU2013306390B2 true AU2013306390B2 (en) 2018-07-05

Family

ID=50150288

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2013306390A Active AU2013306390B2 (en) 2012-08-24 2013-03-15 Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
AU2018241099A Active AU2018241099B2 (en) 2012-08-24 2018-10-04 Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
AU2020267172A Abandoned AU2020267172A1 (en) 2012-08-24 2020-11-10 Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2018241099A Active AU2018241099B2 (en) 2012-08-24 2018-10-04 Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
AU2020267172A Abandoned AU2020267172A1 (en) 2012-08-24 2020-11-10 Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis

Country Status (20)

Country Link
US (5) US9758591B2 (enExample)
EP (3) EP2888283B1 (enExample)
JP (4) JP6479660B2 (enExample)
KR (3) KR101935088B1 (enExample)
CN (2) CN104662044B (enExample)
AU (3) AU2013306390B2 (enExample)
BR (1) BR112015003757B1 (enExample)
CA (1) CA2881966C (enExample)
CL (1) CL2015000431A1 (enExample)
DK (3) DK2888283T3 (enExample)
ES (3) ES2992753T3 (enExample)
IL (2) IL236962B (enExample)
MX (1) MX362456B (enExample)
MY (1) MY181648A (enExample)
NI (1) NI201500024A (enExample)
PH (1) PH12015500390B1 (enExample)
PL (2) PL2888283T3 (enExample)
PT (1) PT2888283T (enExample)
SG (1) SG11201500730XA (enExample)
WO (1) WO2014031174A1 (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101935088B1 (ko) 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
CA2939305A1 (en) 2014-02-27 2015-09-03 Lycera Corporation Adoptive cellular therapy using an agonist of retinoic acid receptor-related orphan receptor gamma & related therapeutic methods
EP3209641A4 (en) 2014-05-05 2018-06-06 Lycera Corporation Benzenesulfonamido and related compounds for use as agonists of ror and the treatement of disease
EP3140291A4 (en) 2014-05-05 2018-01-10 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
AU2015295349B2 (en) * 2014-07-29 2020-09-24 Cellectis ROR1(NTRKR1)specific chimeric antigen receptors for cancer immunotherapy
JP2017522893A (ja) 2014-07-31 2017-08-17 セレクティスＣｅｌｌｅｃｔｉｓ Ｒｏｒ１特異的多重鎖キメラ抗原受容体
US20170260261A1 (en) 2014-08-28 2017-09-14 Bioatla, Llc Conditionally Active Chimeric Antigen Receptors for Modified T-Cells
AU2015310897B2 (en) 2014-09-04 2020-03-19 Cellectis Trophoblast glycoprotein (5T4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
JP6865688B2 (ja) * 2015-01-16 2021-04-28 ジュノー セラピューティクス インコーポレイテッド Ｒｏｒ１に特異的な抗体およびキメラ抗原受容体
EP3286214B1 (en) * 2015-04-24 2023-12-06 The Regents of the University of California Modulators of ror1-ror2 binding
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションＬｙｃｅｒａ Ｃｏｒｐｏｒａｔｉｏｎ ＲＯＲγの作動薬及び疾患の療法として使用するジヒドロ−２Ｈ−ベンゾ［ｂ］［１，４］オキサジンスルホンアミド及び関連化合物
WO2016187220A2 (en) * 2015-05-18 2016-11-24 Five Prime Therapeutics, Inc. Anti-ror1 antibodies
TW201706300A (zh) 2015-05-20 2017-02-16 瑟勒提斯公司 用於癌症免疫療法之抗－ｇｄ３專一性嵌合抗原受體
CA2987289A1 (en) 2015-06-11 2016-12-15 Lycera Corporation Aryl dihydro-2h-benzo[b][1,4]oxazine sulfonamide and related compounds for use as agonists of ror.gamma. and the treatment of disease
JP6998768B2 (ja) * 2015-08-28 2022-02-10 ロート製薬株式会社 Ｒｏｒ１陽性の間葉系幹細胞及びその調製方法、ｒｏｒ１陽性の間葉系幹細胞を含む医薬組成物及びその調製方法、並びにｒｏｒ１陽性の間葉系幹細胞を用いる疾患の予防又は治療方法
AU2016345681A1 (en) 2015-10-30 2018-05-10 Nbe-Therapeutics Ag Anti-ROR1 antibodies
KR20180101554A (ko) * 2016-01-20 2018-09-12 더 스크립스 리서치 인스티튜트 Ｒｏｒ１ 항체 조성물 및 관련 방법
CN108495864A (zh) * 2016-01-22 2018-09-04 詹森生物科技公司 抗ror1抗体、ror1×cd3双特异性抗体及其使用方法
CN108699149B (zh) 2016-02-02 2023-01-06 弗雷德哈钦森癌症中心 抗-ror1抗体及其用途
PL3455261T3 (pl) * 2016-05-13 2022-12-12 Bioatla, Inc. Przeciwciała anty-ror2, fragmenty przeciwciał, ich immunokoniugaty oraz ich zastosowania
WO2018005519A2 (en) 2016-06-27 2018-01-04 The Regents Of The University Of California Cancer treatment combinations
WO2018119314A1 (en) * 2016-12-22 2018-06-28 Ardeagen Corporation Anti-ror1 antibody and conjugates thereof
AU2018289581C1 (en) 2017-06-23 2025-01-30 VelosBio Inc. ROR1 antibody immunoconjugates
CN110799539B (zh) * 2017-06-25 2023-08-15 西雅图免疫公司 抗4-1bb抗体及其制备和使用方法
CN116199785A (zh) * 2017-06-25 2023-06-02 西雅图免疫公司 多特异性抗体及其制备和使用方法
GB201710838D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc Bispecific antibodies
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
GB201710836D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Car T-Cells
EP3665193A1 (en) 2017-08-07 2020-06-17 NBE Therapeutics AG Anthracycline-based antibody drug conjugates having high in vivo tolerability
US12350312B2 (en) 2017-09-06 2025-07-08 Fred Hutchinson Cancer Center Methods for improving adoptive cell therapy
EP3697435A1 (en) 2017-10-20 2020-08-26 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
CN109836498A (zh) * 2017-11-25 2019-06-04 深圳宾德生物技术有限公司 一种靶向ror1的单链抗体、嵌合抗原受体t细胞及其制备方法和应用
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
US20210079061A1 (en) 2018-02-26 2021-03-18 Fred Hutchinson Cancer Research Center Compositions and methods for cellular immunotherapy
AU2019231321A1 (en) * 2018-03-09 2020-10-15 The Regents Of The University Of California Combination treatment of chemoresistant cancers
CN112384533A (zh) * 2018-04-18 2021-02-19 埃克塞里艾克西斯公司 抗-ror抗体构建体
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
MX2021009087A (es) 2019-01-29 2021-09-08 Juno Therapeutics Inc Anticuerpos y receptores quimericos de antigenos especificos para receptor 1 huerfano tipo receptor tirosina-cinasa (ror1).
AU2020248448A1 (en) * 2019-03-26 2021-10-14 The Regents Of The University Of California Chimeric antigen receptor modified T-cells (CAR-T) for the treatment of hematological and solid tumor cancers
CN113874399B (zh) * 2019-05-23 2025-07-11 维洛斯生物股份有限公司 抗ror1/抗cd3双特异性结合分子
AU2021214581A1 (en) * 2020-01-30 2022-09-01 Ho'ola Therapeutics Inc. Combinations of EGFR inhibitors and ROR1 inhibitors for the treatment of cancer
AU2021217173A1 (en) * 2020-02-07 2022-08-11 VelosBio Inc. Anti-ROR1 antibodies and compositions
CN112522206A (zh) * 2020-12-15 2021-03-19 苏州恒康生命科学有限公司 一种ror1基因敲除肿瘤细胞株的构建方法及其应用
GB202020154D0 (en) 2020-12-18 2021-02-03 Almac Discovery Ltd ROR1-specific variant antigen binding molecules
CA3208781A1 (en) 2021-02-02 2022-08-11 Bithi CHATTERJEE Multispecific antibodies having specificity for ror1 and cd3
KR20230148837A (ko) 2021-02-25 2023-10-25 라이엘 이뮤노파마, 인크. Ror1 표적화 키메라 항원 수용체
CN117440973A (zh) * 2021-04-09 2024-01-23 索伦托药业有限公司 与ror1结合的抗原结合蛋白
US11806405B1 (en) 2021-07-19 2023-11-07 Zeno Management, Inc. Immunoconjugates and methods
EP4385522A1 (en) 2021-08-13 2024-06-19 Kunshan Xinyunda Biotech Co., Ltd. Microtubule inhibitor-based antibody-drug conjugate
US20240392033A1 (en) 2021-08-24 2024-11-28 Kunshan Xinyunda Biotech Co., Ltd. Antibody-drug conjugate conjugated via breakable linker
IL312204A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culturing cells expressing ror1-binding protein
CN118401258A (zh) 2021-12-09 2024-07-26 昆山新蕴达生物科技有限公司 一种亲和力改善的抗体-药物偶联物、其制备方法及应用
CN116836286A (zh) 2022-09-07 2023-10-03 中国科学院合肥物质科学研究院 能够特异性结合ror1的抗体、其偶联药物及其制备方法和应用
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103849A2 (en) * 2007-02-21 2008-08-28 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
WO2012097313A2 (en) * 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same

Family Cites Families (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4714681A (en) 1981-07-01 1987-12-22 The Board Of Reagents, The University Of Texas System Cancer Center Quadroma cells and trioma cells and methods for the production of same
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
ATE120454T1 (de) 1988-06-14 1995-04-15 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US4925648A (en) 1988-07-29 1990-05-15 Immunomedics, Inc. Detection and treatment of infectious and inflammatory lesions
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5225538A (en) 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
IE63847B1 (en) 1989-05-05 1995-06-14 Res Dev Foundation A novel antibody delivery system for biological response modifiers
DE69029036T2 (de) 1989-06-29 1997-05-22 Medarex Inc Bispezifische reagenzien für die aids-therapie
CA2050918A1 (en) 1990-01-12 1991-07-13 Raju Kucherlapati Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
JP3319594B2 (ja) 1990-03-20 2002-09-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5219837A (en) 1990-06-21 1993-06-15 Trustees Of The University Of Pennsylvania Method of stimulating myelination of cells
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2129029T5 (es) 1990-10-05 2005-10-16 Celldex Therapeutics, Inc. Inmunoestimulacion dirigida con reactivos biespecificos.
US5858725A (en) 1990-10-10 1999-01-12 Glaxo Wellcome Inc. Preparation of chimaeric antibodies using the recombinant PCR strategy
AU8727291A (en) 1990-10-29 1992-06-11 Cetus Oncology Corporation Bispecific antibodies, method of production, and uses thereof
DK0574395T3 (da) 1990-11-09 2002-10-07 Stephen D Gillies Cytokin-immunkonjugater
CA2108451A1 (en) 1991-04-26 1992-10-27 Beverley J. Randle Novel antibodies, and methods for their use
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
US5843749A (en) 1991-07-26 1998-12-01 Regeneron Pharmaceuticals, Inc. Ehk and Ror tyrosine kinases
ES2193143T3 (es) 1992-03-05 2003-11-01 Univ Texas Uso de inmunoconjugados para la diagnosis y/o terapia de tumores vascularizaos.
US5855885A (en) 1993-01-22 1999-01-05 Smith; Rodger Isolation and production of catalytic antibodies using phage technology
US7473423B2 (en) 1994-04-29 2009-01-06 Mayo Foundation For Medical Education And Research Human IgM antibodies, and diagnostic and therapeutic uses thereof particularly in the central nervous system
DK0807173T3 (da) 1994-12-30 2008-01-07 Univ California Fremgangsmåder til fremstilling af immunoglobuliner indeholdende beskyttelsesproteiner i planter og anvendelse deraf
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0833911B1 (en) 1995-06-07 2004-05-12 Ortho Pharmaceutical Corporation Cdr-grafted anti-tissue factor antibodies and methods of use thereof
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
WO1998041541A1 (en) 1997-03-19 1998-09-24 Johns Hopkins University Therapeutic uses of grip and grip-related molecules
US6287569B1 (en) 1997-04-10 2001-09-11 The Regents Of The University Of California Vaccines with enhanced intracellular processing
DE69841273D1 (de) 1997-11-17 2009-12-17 Micromet Ag Verfahren zur identifikation von bindestellendomänen, die ihre epitopbindefähigkeit beibehalten
HUP0101160A2 (hu) 1998-04-03 2001-08-28 Chugai Seiyaku Kabushiki Kaisha Humán szöveti faktor (TF) elleni humanizált antitest és eljárás előállítására
US6897044B1 (en) 1999-01-28 2005-05-24 Biogen Idec, Inc. Production of tetravalent antibodies
US6605709B1 (en) 1999-04-09 2003-08-12 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Proteus mirabilis for diagnostics and therapeutics
WO2001070266A2 (en) 2000-03-17 2001-09-27 Millennium Pharmaceuticals, Inc. Method of inhibiting stenosis and restenosis with a mixture of antibodies anti cd18 and anti ccr2
ATE494304T1 (de) 2000-06-16 2011-01-15 Human Genome Sciences Inc Immunspezifisch bindende antikörper gegen blys
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US7214786B2 (en) 2000-12-14 2007-05-08 Kovalic David K Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
US20140072980A1 (en) 2001-01-16 2014-03-13 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US20140072979A1 (en) 2001-01-16 2014-03-13 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
US6919183B2 (en) 2001-01-16 2005-07-19 Regeneron Pharmaceuticals, Inc. Isolating cells expressing secreted proteins
AU2002327164A1 (en) 2001-01-29 2002-12-09 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
US20030020733A1 (en) 2001-07-24 2003-01-30 Yin Memphis Zhihong Computer display having selective area magnification
EP1425694A2 (en) 2001-08-03 2004-06-09 Medical Research Council Method of identifying a consensus sequence for intracellular antibodies
EP2383290B1 (en) 2001-08-23 2019-05-08 Rsr Limited Epitope regions of a thyrotropin (tsh) receptor, uses thereof and antibodies thereto
WO2003040340A2 (en) 2001-11-07 2003-05-15 Agensys, Inc. Nucleic acid and corresponding protein entitled 161p2f10b useful in treatment and detection of cancer
EP1464702A4 (en) 2001-12-28 2005-09-21 Chugai Pharmaceutical Co Ltd METHOD FOR PROTEIN STABILIZATION
WO2003068924A2 (en) 2002-02-13 2003-08-21 Ludwig Institute For Cancer Research Fusion proteins of humanized g250 specific antibodies and uses thereof
US7314974B2 (en) 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
KR100788093B1 (ko) 2002-04-26 2007-12-21 제넨테크, 인크. 단백질의 비친화성 정제
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
WO2004009805A1 (ja) 2002-07-19 2004-01-29 Japan Science And Technology Agency 新規抗体酵素生産方法、新規抗体酵素、およびその利用
DE60336406D1 (de) 2002-10-16 2011-04-28 Purdue Pharma Lp Antikörper, die an zellassoziiertes ca 125/0722p binden, und verfahren zu deren anwendung
JP2006517109A (ja) 2003-02-07 2006-07-20 プロテイン デザイン ラブス インコーポレイテッド アンフィレグリン抗体ならびに癌および乾癬を処置するためのその使用
US7605235B2 (en) 2003-05-30 2009-10-20 Centocor, Inc. Anti-tissue factor antibodies and compositions
CA2522894C (en) 2003-05-31 2013-06-25 Micromet Ag Pharmaceutical composition comprising a bispecific antibody specific for epcam
US7569389B2 (en) 2004-09-30 2009-08-04 Ceres, Inc. Nucleotide sequences and polypeptides encoded thereby useful for modifying plant characteristics
AU2003271174A1 (en) 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
HRP20110187T1 (hr) 2003-10-16 2011-04-30 Micromet Ag Multispecifične deimunizirane tvari koje vežu cd3
US7612179B2 (en) 2003-11-28 2009-11-03 Astrazeneca Ab antibodies binding to a C-terminal fragment of apoliopoprotein E
US20050191293A1 (en) 2003-12-10 2005-09-01 Shrikant Deshpande IP-10 antibodies and their uses
ES2364147T3 (es) 2004-01-16 2011-08-25 Regeneron Pharmaceuticals, Inc. Polipéptidos de fusión capaces de activar receptores.
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
SI1716178T1 (sl) 2004-02-16 2010-11-30 Micromet Ag Manj imunogene vezne molekule
DE602005018325D1 (de) 2004-02-19 2010-01-28 Genentech Inc Antikörper mit korrigierten cdr
US7192709B2 (en) 2004-03-15 2007-03-20 Digigenomics Co., Ltd. Methods for identification, assessment, prevention, and therapy of cancer
US7504086B2 (en) 2004-03-31 2009-03-17 Canon Kabushiki Kaisha Structure and method for releasing substance therefrom
CA2563333A1 (en) 2004-04-06 2005-10-27 The Regents Of The University Of California Orphan receptor tyrosine kinase as a target in breast cancer
US7625561B2 (en) 2004-04-22 2009-12-01 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Diabody which specifically binds Streptococcus surface antigen I/II and methods of use thereof
JPWO2005105998A1 (ja) 2004-04-27 2008-07-31 財団法人化学及血清療法研究所 ヒト抗アミロイドβペプチド抗体およびその抗体フラグメント
UY28886A1 (es) 2004-05-10 2005-12-30 Boehringer Ingelheim Int Anticuerpos que consisten en polipéptidos y derivados conprendiendo tres secuencias conteniendo respectivamente los siguientes números de seq. id: 1-3 y 4-6; 7-9 y 10-12 y 13-15 ó 16-18
JP2008507592A (ja) 2004-06-09 2008-03-13 ジェネンテック・インコーポレーテッド 環状肉芽腫又はサルコイドの治療法
EP1778845A2 (en) 2004-08-16 2007-05-02 CropDesign N.V. Plants having improved growth characteristics and method for making the same
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
DE602005026219D1 (de) 2004-10-01 2011-03-17 Max Planck Gesellschaft Gegen das säugetier-eag1-ionenkanalprotein gerichtete antikörper
CA2591665C (en) 2004-12-20 2015-05-05 Crucell Holland B.V. Binding molecules capable of neutralizing west nile virus and uses thereof
CA2595276C (en) 2005-01-27 2014-03-11 Novimmune S.A. Anti-interferon gamma antibodies and methods of use thereof
US8088976B2 (en) 2005-02-24 2012-01-03 Monsanto Technology Llc Methods for genetic control of plant pest infestation and compositions thereof
CA2603414C (en) 2005-03-31 2012-09-18 Biomedics Inc. Anti-cd20 monoclonal antibody
JP5004154B2 (ja) 2005-04-06 2012-08-22 一般財団法人化学及血清療法研究所 組換え抗ボツリヌス神経毒素抗体
KR100978684B1 (ko) 2005-04-22 2010-08-31 일라이 릴리 앤드 캄파니 Ｔｇｆ 베타 1 특이적 항체
WO2006138005A2 (en) 2005-05-10 2006-12-28 Monsanto Technology, Llc Genes and uses for plant improvement
US7736647B2 (en) 2005-06-15 2010-06-15 Monoclonal Antibodies Therapeutics Anti-CD71 monoclonal antibodies and uses thereof for treating malignant tumor cells
HUE032131T2 (en) 2005-08-31 2017-09-28 Merck Sharp & Dohme Constructed anti-IL-23 antibodies
EP1948680A4 (en) 2005-10-28 2010-01-13 Univ California METHOD AND COMPOUNDS FOR DETECTING AND ISOLATING LYMPHOMA CELLS
US8716195B2 (en) 2005-11-14 2014-05-06 Bioren, Inc. Antibody ultrahumanization by predicted mature CDR blasting and cohort library generation and screening
EP2548955A1 (en) 2006-02-14 2013-01-23 Verenium Corporation Xylanases, nucleic acids encoding them and methods for making and using them
JPWO2007102200A1 (ja) 2006-03-07 2009-07-23 国立大学法人大阪大学 抗ｃｄ２０モノクローナル抗体
WO2007146957A2 (en) 2006-06-13 2007-12-21 Irm Llc Ror1 as a therapeutic target for lung cancer
WO2008021290A2 (en) 2006-08-09 2008-02-21 Homestead Clinical Corporation Organ-specific proteins and methods of their use
GEP20125612B (en) 2006-08-18 2012-08-27 Novartis Ag Prlr-specific antibody and usage thereof
PL2066694T3 (pl) 2006-09-29 2016-04-29 Oncomed Pharm Inc Kompozycje i sposoby diagnozowania i leczenia nowotworu
US7718774B2 (en) 2006-11-08 2010-05-18 Macrogenics, Inc. TES7 and antibodies that bind thereto
FR2909092B1 (fr) 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
WO2008076868A2 (en) 2006-12-18 2008-06-26 Abbott Laboratories Methods and compositions related to modulation of receptor tyrosine kinase orphan receptor-1 (ror-1)
MX2009006879A (es) 2006-12-22 2009-07-03 Schering Corp Anticuerpos contra el cd200r.
US8298545B2 (en) 2007-02-07 2012-10-30 The Trustees Of The University Of Pennsylvania Anti-autoimmune antibodies for treatment of pemphigus
US9745367B2 (en) 2007-03-23 2017-08-29 Novelmed Theraputics, Inc. Alternative pathway specific antibodies for treating arthritis
US8163279B2 (en) 2007-04-13 2012-04-24 Stemline Therapeutics, Inc. IL3Rα antibody conjugates and uses thereof
WO2008137629A2 (en) 2007-05-03 2008-11-13 Regeneron Pharmaceuticals, Inc. Identifying germline competent embryonic stem cells
MX2009012282A (es) 2007-05-17 2009-11-25 Genentech Inc Estructuras cristalinas de fragmentos de neuropilina y complejos de neuropilina-anticuerpos.
US8546546B2 (en) 2007-07-04 2013-10-01 Forerunner Pharma Research Co., Ltd. Anti-Muc 17 antibody
US8299318B2 (en) 2007-07-05 2012-10-30 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
US8119130B2 (en) 2007-07-25 2012-02-21 Medimmune Limited Targeted binding agents directed to KDR and uses thereof—035
US20110263825A1 (en) 2007-09-06 2011-10-27 Osaka University Anti-cd20 monoclonal antibodies
US8362325B2 (en) 2007-10-03 2013-01-29 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
WO2009052431A2 (en) 2007-10-19 2009-04-23 Seattle Genetics, Inc. Cd19 binding agents and uses thereof
US8715941B2 (en) 2007-11-16 2014-05-06 Arca Biopharma, Inc. Antibodies to LRP6
TW201634479A (zh) 2007-12-05 2016-10-01 Chugai Pharmaceutical Co Ltd 抗ｎｒ１０抗體及其應用
US7960515B2 (en) 2007-12-14 2011-06-14 Bristol-Myers Squibb Company Binding molecules to the human OX40 receptor
US8147836B2 (en) 2007-12-17 2012-04-03 Dyax Corp. Compositions and methods for treating osteolytic disorders comprising MMP-14 binding proteins
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
CA2710680C (en) 2007-12-26 2018-10-16 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
WO2009097128A1 (en) 2008-01-29 2009-08-06 Ludwig Institute For Cancer Research Ltd. Membrane transporter napi2b (slc34a2) epitope for antibody therapy, antibodies directed thereto, and target for cancer therapy
WO2009099580A2 (en) 2008-02-05 2009-08-13 Monsanto Technology, Llc Isolated novel nucleic acid and protein molecules from soy and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
CN104548091A (zh) 2008-02-11 2015-04-29 治疗科技公司 用于肿瘤治疗的单克隆抗体
JP2011517662A (ja) 2008-03-03 2011-06-16 ダイアックス コーポレーション メタロプロテアーゼ９結合タンパク質
US8168757B2 (en) 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
EP2282757B1 (en) 2008-04-07 2013-05-22 Kalobios Pharmaceuticals, Inc. Neutralization of gm-csf for the treatment of heart failure
EP2280997A2 (en) 2008-04-18 2011-02-09 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
NZ588554A (en) 2008-04-29 2013-03-28 Abbott Lab Dual variable domain immunoglobulins and uses thereof
WO2009154026A1 (ja) 2008-06-20 2009-12-23 国立大学法人岡山大学 石灰化小球に対する抗体及びその用途
US8187601B2 (en) 2008-07-01 2012-05-29 Aveo Pharmaceuticals, Inc. Fibroblast growth factor receptor 3 (FGFR3) binding proteins
EP2313109A2 (en) 2008-07-02 2011-04-27 Emergent Product Development Seattle, LLC Il6 immunotherapeutics
CA2730776C (en) 2008-07-16 2018-12-11 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
US8710022B2 (en) 2008-07-18 2014-04-29 National University Corporation Nagoya University Cell proliferation inhibitor
EP2318535A2 (en) 2008-07-31 2011-05-11 BASF Plant Science GmbH Plants having modified growth characteristics and a method for making the same
WO2010021874A2 (en) 2008-08-20 2010-02-25 Centocor Ortho Biotech Inc. Engineered anti-il-13 antibodies, compositions, methods and uses
CA2740900C (en) 2008-11-03 2019-09-24 Alethia Biotherapeutics Inc. Antibodies that specifically block the biological activity of a tumor antigen
US8183346B2 (en) 2008-12-05 2012-05-22 Eli Lilly And Company Anti-ferroportin 1 monoclonal antibodies and uses thereof
WO2010083179A2 (en) 2009-01-16 2010-07-22 Monsanto Technology Llc Isolated novel nucleic acid and protein molecules from soybeans and methods of using those molecules to generate transgenic plants with enhanced agronomic traits
US8673307B1 (en) 2009-03-09 2014-03-18 The Rockefeller University HIV-1 anti-core neutralizing antibodies that target a conformational epitope within the ALPHA5-helix of GP120
MY162752A (en) 2009-03-20 2017-07-14 Amgen Inc Alpha-4-beta-7 heterodimer specific antagonist antibody
CA2756186A1 (en) 2009-03-24 2010-09-30 Teva Biopharmaceuticals Usa, Inc. Humanized antibodies against light and uses thereof
DK3702371T5 (da) 2009-03-25 2024-08-26 Genentech Inc Anti-FGFR3-antistoffer og fremgangsmåder ved anvendelse af disse
US8722046B2 (en) 2009-04-08 2014-05-13 The United States Of America As Represented By The Secretary Of The Army Human monoclonal antibodies protective against bubonic plague
ES2641612T3 (es) 2009-04-17 2017-11-10 Immunas Pharma, Inc. Anticuerpos que se unen específicamente a oligómeros de beta A y uso de los mismos
EP2421899B1 (en) * 2009-04-23 2016-06-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-human ror1 antibodies
CA2759233C (en) 2009-04-27 2019-07-16 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PL2464664T3 (pl) 2009-08-13 2016-02-29 Crucell Holland Bv Przeciwciała przeciwko ludzkiemu syncytialnemu wirusowi oddechowemu (RSV) i sposoby zastosowania
KR101778813B1 (ko) 2009-08-28 2017-09-14 리제너론 파마슈티칼스 인코포레이티드 다수의 ｃｃ 케모카인에 결합하는 항카인 항체
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
WO2011038290A2 (en) 2009-09-25 2011-03-31 The U. S. A., As Represented By The Secretary, Department Of Health And Human Services Neutralizing antibodies to hiv-1 and their use
US8580714B2 (en) 2009-10-14 2013-11-12 Janssen Biotech, Inc. Methods of affinity maturing antibodies
CN102596996B (zh) 2009-10-30 2014-06-18 东丽株式会社 对丙型肝炎病毒(hcv)具有感染抑制活性的抗体及其用途
EP2496605A1 (en) 2009-11-02 2012-09-12 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
CN106432500B (zh) 2009-11-11 2020-06-02 加尼梅德药物公司 密蛋白6(cldn6)特异性的抗体
WO2011084496A1 (en) 2009-12-16 2011-07-14 Abbott Biotherapeutics Corp. Anti-her2 antibodies and their uses
EP2513146B1 (en) 2009-12-18 2017-05-03 Kancera AB Antibodies against ror1 capable of inducing cell death of cll
JP6034696B2 (ja) 2010-02-12 2016-11-30 オンコメッド ファーマシューティカルズ インコーポレイテッド ポリペプチド発現細胞の同定及び単離の方法
JP6039428B2 (ja) 2010-03-04 2016-12-07 シムフォゲン・アクティーゼルスカブＳｙｍｐｈｏｇｅｎ Ａ／Ｓ 抗ｈｅｒ２抗体および組成物
US8609095B2 (en) 2010-03-04 2013-12-17 Symphogen A/S Anti-HER2 antibodies and compositions
BR112012022046A2 (pt) 2010-03-05 2017-02-14 F Hoffamann-La Roche Ag ''anticorpo,composição farmacêutica,ácido nucleico ,vetores de expressão,célula hospedeira e método para a produção de um anticorpo recombinante''.
US8468130B2 (en) 2010-04-02 2013-06-18 Skyfire Labs, Inc. Assisted hybrid mobile browser
US9073990B2 (en) 2010-04-05 2015-07-07 Bar-Llan University Protease-activatable pore-forming polypeptides
CA2799746C (en) 2010-05-17 2020-11-24 Sai Reddy Rapid isolation of monoclonal antibodies from animals
AR081434A1 (es) 2010-06-10 2012-08-29 Lilly Co Eli Anticuerpo del peptido relacionado con el gen calcitonina (cgrp), composicion farmaceutica que lo comprende, uso de dicho anticuerpo para preparar un medicamento util para tratar dolor de osteoartritis o migranas y fragmento de union a antigeno de dicho anticuerpo
JP2012021943A (ja) 2010-07-16 2012-02-02 National Cancer Center 子宮体がんの検査方法、子宮体がんの検査薬、並びに子宮体がん抗原に対する抗体
US9163258B2 (en) 2010-07-23 2015-10-20 Fred Hutchinson Cancer Research Center Method for the treatment of obesity
WO2012038315A1 (en) 2010-09-22 2012-03-29 Novo Nordisk A/S Therapeutic factor viii antibodies
EP2621954A1 (en) 2010-10-01 2013-08-07 Oxford Biotherapeutics Ltd. Anti-rori antibodies
AU2011320314B2 (en) 2010-10-29 2015-08-06 Immunogen, Inc. Novel EGFR-binding molecules and immunoconjugates thereof
JO3756B1 (ar) 2010-11-23 2021-01-31 Regeneron Pharma اجسام مضادة بشرية لمستقبلات الجلوكاجون
EP2455403A1 (en) 2010-11-23 2012-05-23 Pierre Fabre Medicament Homogeneous humanized antibodies against JAM-A that inhibit proliferation
ES2657970T3 (es) * 2010-12-01 2018-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticuerpos contra ROR1 de conejo/ser humano quiméricos
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
WO2012094587A1 (en) 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
TW201245223A (en) 2011-02-14 2012-11-16 Theraclone Sciences Inc Compositions and methods for the therapy and diagnosis of influenza
WO2012118693A1 (en) 2011-02-28 2012-09-07 Northshore University Healthsystem Methods of diagnosing clostridium difficile infection
SI3505531T1 (sl) 2011-04-22 2024-02-29 Wyeth Llc Kompozicije, povezane z mutantnim toksinom clostridium difficile in njegovimii metodami
UA115969C2 (uk) 2011-05-13 2018-01-25 Ганімед Фармасьютікалз Аг Антитіло для лікування ракових захворювань, при яких експресується клаудин 6
WO2013019730A1 (en) 2011-07-29 2013-02-07 The Washington University Antibodies to tip-1 and grp78
EP2742067A4 (en) 2011-08-12 2015-03-04 Omeros Corp MONOCLONAL FZD10 ANTIBODIES AND METHOD FOR THEIR USE
HRP20230078T1 (hr) 2011-09-23 2023-05-12 Mereo Biopharma 5, Inc. Sredstva za vezivanje vegf/dll4 i njihova uporaba
SMT202000091T1 (it) 2011-10-13 2020-05-08 Bristol Myers Squibb Co Polipeptidi anticorpali che antagonizzano cd40l
EP2589609A1 (en) 2011-11-03 2013-05-08 Pierre Fabre Medicament Antigen binding protein and its use as addressing product for the treatment of cancer
EP2617319A1 (en) 2012-01-17 2013-07-24 Braun GmbH Head portion and handle portion of an oral care device
US9273130B2 (en) 2012-02-21 2016-03-01 Toray Industries, Inc. Pharmaceutical composition for treatment and/or prevention of cancer
RU2631804C2 (ru) 2012-02-21 2017-09-26 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения или профилактики рака
HUE037021T2 (hu) 2012-02-24 2018-08-28 Abbvie Stemcentrx Llc DLL3- modulátorok és eljárások alkalmazásukra
EP2832856A4 (en) 2012-03-29 2016-01-27 Chugai Pharmaceutical Co Ltd ANTI-LAMP5 ANTIBODIES AND USE THEREOF
RU2649802C2 (ru) 2012-03-30 2018-04-04 Торэй Индастриз, Инк. Фармацевтическая композиция для лечения и/или предотвращения рака желчного пузыря
ES2656620T3 (es) 2012-03-30 2018-02-27 Toray Industries, Inc. Composición farmacéutica para el tratamiento y/o la prevención del cáncer de hígado
JP6244350B2 (ja) 2012-04-03 2017-12-06 ノーベルメッド セラピューティクス インコーポレイテッド． ヒト化およびキメラ抗因子Ｂｂ抗体、ならびにその使用
AR090903A1 (es) 2012-05-01 2014-12-17 Genentech Inc Anticuerpos e inmunoconjugados anti-pmel17
US9580514B2 (en) 2012-05-14 2017-02-28 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
CN103421113B (zh) 2012-05-22 2018-01-19 武汉华鑫康源生物医药有限公司 抗BLyS抗体
JO3462B1 (ar) 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
KR101935088B1 (ko) * 2012-08-24 2019-01-04 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 Ror1 암을 치료하고 전이를 저해하는데 이용을 위한 항체와 백신
CN103792364B (zh) 2012-10-31 2016-06-08 张宝弘 用于检测外周血中循环肿瘤细胞ror1蛋白的试剂及其应用
TWI675044B (zh) 2012-11-14 2019-10-21 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
ME03394B (me) 2013-02-22 2020-01-20 Medimmune Ltd Antidllз-antitelo-pbd konjugati i nihovа upotreba
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
JP2016518382A (ja) 2013-04-26 2016-06-23 ピエール、ファーブル、メディカマン Ａｘｌ抗体薬物複合体および癌の治療のためのその使用
EP4324480A3 (en) 2013-05-20 2024-05-08 F. Hoffmann-La Roche AG Anti-transferrin receptor antibodies and methods of use
WO2015014376A1 (en) 2013-07-31 2015-02-05 Biontech Ag Diagnosis and therapy of cancer involving cancer stem cells
WO2015031693A1 (en) 2013-08-28 2015-03-05 Stem Centrx, Inc. Engineered anti-dll3 conjugates and methods of use
JP6515111B2 (ja) 2013-11-06 2019-05-22 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗クローディン抗体および使用方法
CN110951779B (zh) 2013-12-11 2024-04-16 瑞泽恩制药公司 用于靶向修饰基因组的方法和组合物
KR20160098328A (ko) 2013-12-13 2016-08-18 제넨테크, 인크. 항-cd33 항체 및 면역접합체
SG10201809385RA (en) 2013-12-17 2018-11-29 Genentech Inc Anti-cd3 antibodies and methods of use
WO2015099838A2 (en) 2013-12-24 2015-07-02 Novelmed Therapeutics, Inc. Compositions and methods of treating ocular diseases
EA201691683A1 (ru) 2014-02-21 2017-04-28 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Антитела против dll3 и конъюгаты антитело-лекарственное средство для применения при меланоме
PL3126381T5 (pl) 2014-04-01 2022-05-23 Biontech Cell&Gene Therapies Gmbh Immunoreceptory specyficzne dla klaudyny-6 i epitopy komórek t
HRP20192254T1 (hr) 2014-04-25 2020-03-06 Pierre Fabre Medicament Konjugat antitijela i lijeka i njegova upotreba u liječenju karcinoma

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008103849A2 (en) * 2007-02-21 2008-08-28 The Regents Of The University Of California Methods and compounds for lymphoma cell detection and isolation
WO2012097313A2 (en) * 2011-01-14 2012-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BASKAR S. et al., "Targeting Human B Cell Chronic Lymphocytic Leukemia With a Monoclonal Antibody Speci¿c for the Receptor Tyrosine Kinase ROR1", JOURNAL OF IMMUNOTHERAPY, January 2008, vol. 31, no. 9, page 969 *

Also Published As

Publication number Publication date
US9758591B2 (en) 2017-09-12
US12162950B2 (en) 2024-12-10
KR102312856B1 (ko) 2021-10-13
CA2881966A1 (en) 2014-02-27
DK3489261T3 (da) 2020-12-14
ES2992753T3 (en) 2024-12-17
IL264057B (en) 2020-03-31
DK3838923T3 (da) 2024-07-29
WO2014031174A1 (en) 2014-02-27
EP3489261B1 (en) 2020-10-21
ES2845184T3 (es) 2021-07-26
US20190389962A1 (en) 2019-12-26
MY181648A (en) 2020-12-30
AU2013306390A1 (en) 2015-02-26
PH12015500390B1 (en) 2021-12-10
BR112015003757A2 (pt) 2017-11-28
EP2888283A1 (en) 2015-07-01
US20250282888A1 (en) 2025-09-11
BR112015003757B1 (pt) 2022-08-16
MX2015002337A (es) 2015-08-14
US11312787B2 (en) 2022-04-26
KR20150046111A (ko) 2015-04-29
MX362456B (es) 2019-01-18
NI201500024A (es) 2015-07-16
JP6479660B2 (ja) 2019-03-06
JP2022174167A (ja) 2022-11-22
JP2015532644A (ja) 2015-11-12
JP2019110906A (ja) 2019-07-11
CL2015000431A1 (es) 2016-02-26
ES2702315T3 (es) 2019-02-28
CN109369808B (zh) 2023-11-07
IL236962B (en) 2019-01-31
US20180066063A1 (en) 2018-03-08
KR20190000925A (ko) 2019-01-03
EP3838923B1 (en) 2024-05-01
KR20200079561A (ko) 2020-07-03
KR101935088B1 (ko) 2019-01-04
DK2888283T3 (en) 2018-11-19
JP2021058215A (ja) 2021-04-15
AU2018241099A1 (en) 2018-10-25
KR102134088B1 (ko) 2020-07-14
JP6823094B2 (ja) 2021-01-27
PT2888283T (pt) 2018-11-16
US20230110249A1 (en) 2023-04-13
EP2888283A4 (en) 2016-07-13
CN104662044A (zh) 2015-05-27
US10344096B2 (en) 2019-07-09
CN109369808A (zh) 2019-02-22
PH12015500390A1 (en) 2015-04-27
US20150232569A1 (en) 2015-08-20
JP7138735B2 (ja) 2022-09-16
EP3838923A1 (en) 2021-06-23
IL264057A (en) 2019-01-31
CN104662044B (zh) 2018-10-30
PL2888283T3 (pl) 2019-03-29
AU2018241099B2 (en) 2020-08-13
AU2020267172A1 (en) 2020-12-03
CA2881966C (en) 2020-10-06
SG11201500730XA (en) 2015-02-27
PL3489261T3 (pl) 2021-08-16
EP3489261A1 (en) 2019-05-29
EP2888283B1 (en) 2018-09-19

Similar Documents

Publication Publication Date Title
AU2018241099B2 (en) Antibodies and vaccines for use in treating ROR1 cancers and inhibiting metastasis
HK40055783A (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
HK40055783B (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis
HK40005045B (zh) 用於治疗ror1癌症并抑制转移的抗体和疫苗
HK40005045A (en) Antibodies and vaccines for use in treating ror1 cancers and inhibiting metastasis

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)